“Ovarian-Sparing IMRT for Early-Stage Cervical Cancer: Lower Ovarian Dose, Improved Gamma Passing Rates, and Minimal Impact on Treatment Time”

https://pubmed.ncbi.nlm.nih.gov/38115303

Ovarian-sparing IMRT for stage I/II cervical cancer results in lower ovarian dose, improved gamma passing rates, and negligible impact on treatment time, despite slightly decreased plan quality.